George Grunberger1,2,3,4. 1. Grunberger Diabetes Institute, 43494 Woodward Avenue, suite 208, Bloomfield Hills, MI, 48302, USA. grunberger@gdi-pc.com. 2. Internal Medicine and Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA. grunberger@gdi-pc.com. 3. Internal Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI, USA. grunberger@gdi-pc.com. 4. Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic. grunberger@gdi-pc.com.
Abstract
PURPOSE OF REVIEW: There are currently over 40 different drugs in 12 distinct classes approved in the USA to treat patients with type 2 diabetes mellitus. This review summarizes our current knowledge about potential side effects of antidiabetic therapy and attempts to apply it to a clinical practice setting. RECENT FINDINGS: Given the heterogeneity of both the patients and the disease, it is mathematically impossible to test every available drug combination in long-term outcome, prospective, randomized blinded fashion before a clinician decides which agent(s) to prescribe to a specific patient in a given situation. To complicate the clinician's dilemma, there is lack of available tests to predict an individual's response or propensity to side effects. Further, the data available are derived from small, short-term registration trials and typically focus on relative rather than absolute risks of any given drug and do not address the potential adverse outcomes if a patient's diabetes remains untreated. Clinicians have to personalize their choice of antidiabetic therapy based both on the specific characteristics of the patient in front of them (stage of diabetes and its complications, overall health status, socioeconomic situation, other medications present, desire to improve control of diabetes, etc.) and the current knowledge about the relative and absolute balance of benefits and risks of any individual medication in that specific patient. It has to be recognized that this requires constant re-evaluation as database of our experience with antidiabetic therapy expands.
PURPOSE OF REVIEW: There are currently over 40 different drugs in 12 distinct classes approved in the USA to treat patients with type 2 diabetes mellitus. This review summarizes our current knowledge about potential side effects of antidiabetic therapy and attempts to apply it to a clinical practice setting. RECENT FINDINGS: Given the heterogeneity of both the patients and the disease, it is mathematically impossible to test every available drug combination in long-term outcome, prospective, randomized blinded fashion before a clinician decides which agent(s) to prescribe to a specific patient in a given situation. To complicate the clinician's dilemma, there is lack of available tests to predict an individual's response or propensity to side effects. Further, the data available are derived from small, short-term registration trials and typically focus on relative rather than absolute risks of any given drug and do not address the potential adverse outcomes if a patient's diabetes remains untreated. Clinicians have to personalize their choice of antidiabetic therapy based both on the specific characteristics of the patient in front of them (stage of diabetes and its complications, overall health status, socioeconomic situation, other medications present, desire to improve control of diabetes, etc.) and the current knowledge about the relative and absolute balance of benefits and risks of any individual medication in that specific patient. It has to be recognized that this requires constant re-evaluation as database of our experience with antidiabetic therapy expands.
Entities:
Keywords:
Antidiabetic medications; Drug side effects; Treatment of type 2 diabetes; Type 2 diabetes mellitus
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Yehuda Handelsman; Robert R Henry; Zachary T Bloomgarden; Sam Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Ele Ferrannini; Vivian A Fonseca; Alan J Garber; George Grunberger; Derek LeRoith; Guillermo E Umpierrez; Matthew R Weir Journal: Endocr Pract Date: 2016-06-01 Impact factor: 3.443
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Lawrence Blonde; George E Dailey; Serge A Jabbour; Charles A Reasner; Donna J Mills Journal: Curr Med Res Opin Date: 2004-04 Impact factor: 2.580
Authors: Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin Journal: Ann Intern Med Date: 2012-11-06 Impact factor: 25.391
Authors: Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder Journal: N Engl J Med Date: 2016-02-17 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Jeffrey A Hall; Mark Rusten; Raed D Abughazaleh; Beverly Wuertz; Vannesa Souksavong; Paul Escher; Frank Ondrey Journal: Head Neck Date: 2020-06-09 Impact factor: 3.147
Authors: Jesus Ivan Solares-Pascasio; Guillermo Ceballos; Fernando Calzada; Elizabeth Barbosa; Claudia Velazquez Journal: Molecules Date: 2021-02-11 Impact factor: 4.411
Authors: Anne Abot; Eve Wemelle; Patrice D Cani; Claude Knauf; Claire Laurens; Adrien Paquot; Nicolas Pomie; Deborah Carper; Arnaud Bessac; Xavier Mas Orea; Christophe Fremez; Maxime Fontanie; Alexandre Lucas; Jean Lesage; Amandine Everard; Etienne Meunier; Gilles Dietrich; Giulio G Muccioli; Cedric Moro Journal: Gut Date: 2020-10-05 Impact factor: 23.059